Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
- None.
- None.
Insights
The issuance of a broad patent by the Korean Patent Office for Genprex's Reqorsa® Immunogene Therapy in combination with anti-PD-1 and PD-L1 antibodies significantly strengthens the company's intellectual property portfolio. This strategic move not only secures Genprex's market position in South Korea until 2037 but also complements their existing patents in other major markets. The protection of their drug combinations is crucial as they progress through clinical trials, potentially preventing competitors from entering the space with similar therapies.
From a research perspective, the synergy between REQORSA and immune checkpoint inhibitors could represent a significant advancement in the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). REQORSA's mechanism, which involves modifying gene expression to enhance the immune system's ability to fight cancer, when combined with drugs like Keytruda® and Tecentriq®, which block the PD-1/PD-L1 pathway, may improve patient outcomes by overcoming resistance to these therapies.
As an oncologist, the clinical implications of Genprex's REQORSA in combination with established immune checkpoint inhibitors are promising. For patients with late-stage NSCLC and ES-SCLC, the addition of REQORSA could potentially offer a new line of treatment post-immune checkpoint inhibitor therapy. The Fast Track Designations granted by the FDA for both the Acclaim-2 and Acclaim-3 patient populations underscore the urgent need for innovative treatments in these aggressive forms of lung cancer.
It is essential to note that the success of these trials could lead to improved survival rates and quality of life for patients who have limited options after first-line therapies fail. Moreover, the dose-escalation design of the trials aims to find an optimal balance between efficacy and safety, a critical factor in the management of late-stage cancer patients.
The expansion of Genprex's patent portfolio into South Korea is a strategic business decision that could have a positive impact on investor confidence. Patents are a key asset in the biotechnology industry, serving as a barrier to entry for competitors and as a foundation for future licensing deals or partnerships. The market exclusivity until 2037 provides a long runway for potential commercialization and revenue generation from REQORSA, assuming successful trial outcomes and regulatory approvals.
Investors should monitor the progress of the Acclaim-2 and Acclaim-3 clinical trials closely. Positive data from these trials could act as catalysts for the company's stock price, while any setbacks might have the opposite effect. Furthermore, the Fast Track Designation could expedite the review process and potentially lead to quicker market access, which is a significant advantage in the highly competitive oncology market.
Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex's Acclaim-2 and Acclaim-3 clinical trials
This patent will expand on the previously granted patents in the
"We continue to secure exclusivity for our drug combinations of REQORSA with PD-1 antibodies, such as Keytruda® and PD-L1 antibodies, such as Tecentriq®, for the treatment of cancer in some of the largest markets," said Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex. "It is important that we continue to add to our global intellectual property estate and to build protection around our drug combinations as we advance REQORSA through the clinic."
The Acclaim-2 study is a Phase 1/2 clinical trial that has three portions - a Phase 1 dose escalation portion, a Phase 2a expansion portion, and a Phase 2b randomized portion. The Acclaim-2 trial uses a combination of REQORSA and Merck & Co.'s Keytruda® in patients with late-stage non-small cell lung cancer (NSCLC) whose disease has progressed after treatment with Keytruda. Patients are treated at the 0.06 mg/kg dose level in the first cohort of patients and, subject to the Acclaim-2 SRC approval, will be treated at successive dose levels of 0.09 mg/kg and 0.12 mg/kg. Genprex expects to complete enrollment in the Phase 1 dose escalation portion of the Acclaim-2 study in the second half of 2024. Genprex was granted FDA Fast Track Designation for the Acclaim-2 patient population.
The Acclaim-3 study has two portions - a Phase 1 dose escalation portion and a Phase 2 expansion portion. In November 2022 Genprex filed with the FDA the protocol for the Phase 1/2 Acclaim-3 clinical trial using a combination of REQORSA and Genentech's Tecentriq® as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) who develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The Phase 1 portion of the Acclaim-3 study is open for enrollment, and Genprex expects to complete the Phase 1 portion of the study by the second half of 2024. Genprex was granted FDA Fast Track Designation and Orphan Drug Designation for the Acclaim-3 patient population.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2022.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-receives-notice-of-patent-grant-for-korean-patent-claiming-reqorsa-immunogene-therapy-with-pd-1-and-pd-l1-antibodies-to-treat-cancers-302085870.html
SOURCE Genprex, Inc.
FAQ
What is the latest announcement from Genprex regarding patents?
Which patent office issued the Notice of Patent Grant for Genprex's lead drug candidate?
What clinical trials are the expanded patents applicable to?
What is the focus of the Acclaim-2 study?
What is the purpose of the Acclaim-3 study?
